Intranasal administration nanosystems for brain-targeted drug delivery

被引:0
作者
Yue Jiang
Xueting Pan
Tao Yu
Hai Wang
机构
[1] National Center for Nanoscience and Technology,CAS Key Laboratory for Biomedical Effects of Nanomaterials & Nanosafety, CAS Center for Excellence in Nanoscience
[2] University of Chinese Academy of Sciences,Beijing Institute of Functional Neurosurgery, Xuanwu Hospital
[3] Capital Medical University,undefined
来源
Nano Research | 2023年 / 16卷
关键词
intranasal administration; nanosystems; brain-targeted delivery; neurological diseases; drug delivery;
D O I
暂无
中图分类号
学科分类号
摘要
The existence of the blood-brain barrier (BBB) restricts the entry of drugs from the circulation into the central nervous system (CNS), which severely affects the treatment of neurological diseases, including glioblastoma, Parkinson’s disease (PD), and Alzheimer’s disease (AD). With the advantage of bypassing the BBB and avoiding systemic distribution, intranasal administration has emerged as an alternative method of delivering drugs to the brain. Drug delivery directly to the brain using intranasal nanosystems represents a new paradigm for neurological disease treatment because of its advantages in improving drug solubility and stability in vivo, enabling targeted drug delivery and controlled release, and reducing non-specific toxicity. And it has shown efficacy in animal models and clinical applications. Herein, this review describes the mechanisms of intranasal delivery of brain-targeted drugs, the properties of nanosystems for intranasal administration (e.g., liposomes, nanoemulsions, and micelles), and strategies for intranasal drug delivery to enhance brain-targeted drug delivery. Recent applications of nanosystems in intranasal drug delivery and disease treatment have been comprehensively reviewed. Although encouraging results have been reported, significant challenges still need to be overcome to translate these nanosystems into clinics. Therefore, the future prospects of intranasal drug delivery nanosystems are discussed in depth, expecting to provide useful insights and guidance for effective neurological disease treatment. [graphic not available: see fulltext]
引用
收藏
页码:13077 / 13099
页数:22
相关论文
共 1262 条
[61]  
Chen W L(2021)Formation of stable nanoemulsions by ultrasound-assisted two-step emulsification process for topical drug delivery: Effect of oil phase composition and surfactant concentration and loratadine as ripening inhibitor J. Drug Target. 29 199-1031
[62]  
Yao S(2020)Delivery of siRNA to the brain using a combination of nose-to-brain delivery and cell-penetrating peptide-modified nano-micelles Nanoscale 12 13757-4998
[63]  
Wan J(2016)Intranasal brain-targeted clonazepam polymeric micelles for immediate control of status epilepticus: Eur. J. Pharm. Sci. 92 224-4589
[64]  
Tian Y(2020) optimization, Biomaterials 230 119657-5239
[65]  
Huang L(2020) determination of cytotoxicity, Adv. Sci. (Weinh.) 7 1902906-9168
[66]  
Wang S S(2019) biodistribution and pharmacodynamics studies Biomaterials 218 119342-1212
[67]  
Akter F(2019)Intranasal administration of carbamazepine-loaded carboxymethyl chitosan nanoparticles for drug delivery to the brain J. Control. Release 309 37-814
[68]  
Wu Y Q(2021)Superiority of TPGS-loaded micelles in the brain delivery of vinpocetine via administration of thermosensitive intranasal gel J. Pharm. Investig 51 611-459
[69]  
Yao Y Z(2019) and Int. J. Pharm 565 20-552
[70]  
Zhang X C(2020) comparison of curcumin-encapsulated chitosan-coated poly(lactic-co-glycolic acid) nanoparticles and curcumin/hydroxypropyl-β-cyclodextrin inclusion complexes administered intranasally as therapeutic strategies for Alzheimer’s disease Drug Deliv. Transl. Res. 10 1228-53